Canaccord Genuity Raises Price Target for Illumina (NASDAQ: ILMN) Amid Strong Genomics Market Performance

Font: Financial Modeling Prep  • Jul 14, 2026

• Analyst Upgrade & Valuation: Canaccord Genuity increased Illumina's price target to $190.00, aligning with its current market price, reflecting strong business growth in the genomics sequencing technology sector.
• Exceptional Market Performance: Illumina's stock has surged 43.7% year-to-date, significantly outperforming both its industry's 7.5% gain and the S&P 500's 10% increase, driven by robust execution and strong Q1 results.
• Solid Financials & Growth Drivers: The company reported an EPS beat of $1.15 against an estimate of $1.05 and projects continued revenue growth, fueled by the successful NovaSeq X platform adoption and increased demand for clinical sequencing consumables.

On July 14, 2026, an analyst from Canaccord Genuity increased the price target for Illumina (NASDAQ: ILMN). Illumina is a leading company that specializes in genomics sequencing technology. It holds a dominant position in its industry, with a market share of over 90%, as highlighted by Seeking Alpha. The company operates on a "razor-and-blades" model, selling sequencing machines and then generating recurring revenue from the necessary consumables, solidifying its position as a key player in the biotechnology investment landscape.

The analyst raised the price target for Illumina to $190.00 from a previous $140.00. This new target reflects the stock's strong market performance and underlying business growth. At the time of the announcement, the stock was trading at $190.05 per share, showing that the market price was already in line with the analyst's upgraded valuation for this prominent genomics stock.

This optimism is supported by the stock's significant gains in 2026. Shares of Illumina have risen 43.7% year-to-date, which is much higher than the industry's 7.5% gain and the S&P 500's 10% increase. Based on an analysis from Zacks Investment Research, this impressive stock analysis performance is driven by strong execution and first-quarter results that were better than expected, indicating a positive financial outlook.

Key growth drivers include the successful adoption of its NovaSeq X platform, with over 80 units placed. The company also reports a 20% rise in demand for its clinical sequencing consumables outside of China. This shows the effectiveness of its business model, where instrument sales lead to ongoing sales of high-margin supplies, highlighting a strong investment opportunity.

The company's financial health appears solid. In its last report, Illumina announced earnings per share (EPS) of $1.15, beating the estimate of $1.05. For the current fiscal year, projections show earnings of $5.19 per share on $4.56 billion in revenue, with further growth expected in the next fiscal year, underscoring robust revenue growth and an impressive EPS beat.